Major pharma investment, like Lilly's $2.8B deal, is seen as a 'rising tide' that lifts all companies in the psychedelic space. Progress in one area (e.g., DMT) builds momentum for others (e.g., psilocybin, LSD), creating a collaborative effect where individual company advancements benefit the entire industry's legitimacy and growth.
The future market for psychedelic therapies will not be monolithic. Companies are developing drugs that cater to different patient desires, such as the length of the clinical session (a few hours vs. six) and the intensity of the hallucinogenic experience (from a full 'trip' to avoiding it entirely), creating distinct market segments.
An FDA advisory meeting on peptides demonstrated how political influence can predetermine outcomes. New members appointed by Robert F. Kennedy Jr., primarily from industry, voted in a predictable bloc, approving peptides despite FDA objections. This highlights the vulnerability of scientific review processes to political maneuvering, making the votes a foregone conclusion.
Eli Lilly's advertising for Zepbound highlights a key competitive strategy: timing head-to-head trials against a competitor's drug just before a more effective, higher-dose version is approved. This allows Lilly to legally promote a 'dramatic superiority' message based on now-outdated data, forcing Novo Nordisk into a reactive legal battle.
The dynamic between Novo Nordisk and Eli Lilly in the obesity market has evolved. Initially, they worked in parallel to legitimize therapeutic treatment for obesity and combat unregulated compounders. With compounding now restricted, their shared enemies are gone, and the rivalry has escalated into direct, aggressive brand-versus-brand competition, exemplified by Novo's lawsuit.
The ad spending disparity between Eli Lilly ($67.8M/quarter for Zepbound) and Novo Nordisk (not in the top 10) may reflect different corporate cultures. US-based Lilly is native to the aggressive direct-to-consumer (DTC) ad environment. European Novo, from a region where DTC ads are banned, may have a fundamentally different marketing mindset.